Log in to your Inderes Free account to see all free content on this page.
Lytix Biopharma
Less than 1K followers
LYTIX
Euronext Growth Oslo
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
Lytix Biopharma is a clinical-stage biotechnology company developing cancer immunotherapies. The company's technology is based on research into antimicrobial peptides, a defense against pathogens. Lytix Biopharma's lead product, LTX-315, is an oncolytic peptide with the aim of personalizing immunotherapy. The company conducts its research and operations in Oslo, Norway.
Read moreMarket cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
21.5.
2026
Interim report Q1'26
27.8.
2026
Interim report Q2'26
11.11.
2026
Interim report Q3'26
All
Press releases
ShowingAll content types
DNB Carnegie Access: Lytix Biopharma: Complimentary Phase II data to be presented
Lytix Biopharma ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio